me BREAKTHROUGH: Powerful new HIV prevention drug Lencapavir arrives at pivotal moment for SA

South Africa has begun rolling out lenacapavir, a twice-yearly injectable HIV prevention drug hailed as the most significant HIV prevention breakthrough in a generation. Experts say the new option could transform protection for people who struggle with daily medication, while expanding the country’s toolkit against new infections.

On Friday, a young woman in Mpumalanga walked into a clinic and received two injections and two pills that were taken immediately followed by another two to be taken on Saturday to ensure her protection from acquiring HIV for the next six months.

For South Africa, this marked more than the arrival of a new medicine; it marked the beginning of a new chapter in HIV prevention. This is a remarkable moment for South Africa, which has for more than four decades served as both the epicentre of the global HIV epidemic and the cradle of its most resilient responses.

For a young woman in Mpumalanga, a province where nearly one in three women between 25 and 49 live with HIV, a daily pill has never been a simple thing. It requires privacy she may not have, routine her life may not allow, and a willingness to be seen seeking protection in a world that still judges her for needing it.

As a country, South Africa has built one of the world’s largest antiretroviral treatment programmes, demonstrating what political will, community mobilisation and sustained investment can achieve. Yet, it still carries the world’s heaviest HIV burden, with thousands of new infections occurring each year. Today, more people than ever are living longer, healthier lives because they know their status, are on treatment, and are virally suppressed. That progress is hard won and it must be protected while keeping in mind that treatment success alone will not end the epidemic. To bend the curve of new infections, prevention must advance as rapidly as treatment has.

Sustaining the gains of treatment while simultaneously driving down new infections is the defining challenge of this moment. It demands that we expand and strengthen every tool available, and this week, a powerful new one has arrived. SA joins eight other African nations already rolling out Lenacapavir, but given the scale of its epidemic, the strength of its health system, and its historic role in shaping the global Aids response, its adoption carries particular weight for the continent and the world.

The national roll-out of Lenacapavir, a long-acting, twice-yearly injectable pre-exposure prophylaxis, represents the most significant advance in HIV prevention technology in a generation. The evidence